UK Chronic Inflammatory Demyelinating Polyneuropathy Market

ID: MRFR/MED/51236-HCR
200 Pages
Rahul Gotadki
Last Updated: April 02, 2026
UK Chronic Inflammatory Demyelinating Polyneuropathy Market Research Report: Size, Share, Trend Analysis By Diagnosis Type (Electromyography, Nerve Conduction Studies, Lumbar Puncture), By Treatment Type (Immunosuppressive Therapy, Intravenous Immunoglobulin, Plasmapheresis, Corticosteroids), By Distribution Channel (Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics) and By End Users (Hospitals, Research Institutions, Homecare Settings) - Growth Outlook & Industry Forecast 2025 To 2035
UK Chronic Inflammatory Demyelinating Polyneuropathy Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.15%
2024 Market Size$ 74.84 Million
2025 Market Size$ 80.19 Million
2035 Market Size$ 160 Million
Key Players
Bristol-Myers Squibb
Sanofi
Teva Pharmaceutical Industries
Novartis
Roche
Pfizer
Trends
  • Rising Awareness and Diagnosis
  • Advancements in Treatment Options
  • Shift Towards Personalized Medicine
Opportunities
  • Government Initiatives and Funding
  • Rising Demand for Innovative Therapies
  • Technological Advancements in Diagnostics
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Life Sciences, BY Diagnosis Type (USD Million) | |
      1. 4.1.1 Electromyography | |
      2. 4.1.2 Nerve Conduction Studies | |
      3. 4.1.3 Lumbar Puncture |
    2. 4.2 Life Sciences, BY Treatment Type (USD Million) | |
      1. 4.2.1 Immunosuppressive Therapy | |
      2. 4.2.2 Intravenous Immunoglobulin | |
      3. 4.2.3 Plasmapheresis | |
      4. 4.2.4 Corticosteroids |
    3. 4.3 Life Sciences, BY Distribution Channel (USD Million) | |
      1. 4.3.1 Hospitals | |
      2. 4.3.2 Pharmacies | |
      3. 4.3.3 Online Pharmacies | |
      4. 4.3.4 Specialty Clinics |
    4. 4.4 Life Sciences, BY End User (USD Million) | |
      1. 4.4.1 Hospitals | |
      2. 4.4.2 Research Institutions | |
      3. 4.4.3 Homecare Settings 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Life Sciences | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Bristol-Myers Squibb (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Sanofi (FR) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Novartis (CH) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Roche (CH) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Pfizer (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 AstraZeneca (GB) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Eisai (JP) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 UK MARKET ANALYSIS BY DIAGNOSIS TYPE |
    6. 6.3 UK MARKET ANALYSIS BY TREATMENT TYPE |
    7. 6.4 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    8. 6.5 UK MARKET ANALYSIS BY END USER |
    9. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES |
    10. 6.7 RESEARCH PROCESS OF MRFR |
    11. 6.8 DRO ANALYSIS OF LIFE SCIENCES |
    12. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES |
    13. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES |
    14. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES |
    15. 6.12 LIFE SCIENCES, BY DIAGNOSIS TYPE, 2024 (% SHARE) |
    16. 6.13 LIFE SCIENCES, BY DIAGNOSIS TYPE, 2024 TO 2035 (USD Million) |
    17. 6.14 LIFE SCIENCES, BY TREATMENT TYPE, 2024 (% SHARE) |
    18. 6.15 LIFE SCIENCES, BY TREATMENT TYPE, 2024 TO 2035 (USD Million) |
    19. 6.16 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
    20. 6.17 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million) |
    21. 6.18 LIFE SCIENCES, BY END USER, 2024 (% SHARE) |
    22. 6.19 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million) |
    23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    24. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    25. 7.2 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DIAGNOSIS TYPE, 2025-2035 (USD Million) | |
      2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million) | |
      4. 7.2.4 BY END USER, 2025-2035 (USD Million) |
    26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    27. 7.4 ACQUISITION/PARTNERSHIP | |

UK Chronic Inflammatory Demyelinating Polyneuropathy Market Segmentation

UK Chronic Inflammatory Demyelinating Polyneuropathy Market By Diagnosis Type (USD Million, 2025-2035)

  • Electromyography
  • Nerve Conduction Studies
  • Lumbar Puncture

UK Chronic Inflammatory Demyelinating Polyneuropathy Market By Treatment Type (USD Million, 2025-2035)

  • Immunosuppressive Therapy
  • Intravenous Immunoglobulin
  • Plasmapheresis
  • Corticosteroids

UK Chronic Inflammatory Demyelinating Polyneuropathy Market By Distribution Channel (USD Million, 2025-2035)

  • Hospitals
  • Pharmacies
  • Online Pharmacies
  • Specialty Clinics

UK Chronic Inflammatory Demyelinating Polyneuropathy Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Research Institutions
  • Homecare Settings

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.